Arturo Domínguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arturo Domínguez has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Joan Prats
Department of Urology, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Departament de Cirurgia, Sabadell, Spain
3 shared publications- Felipe Couñago
Department of Medicine, Faculty of Medicine, Health and Sports, European University of Madrid, 28108 Madrid, Spain
2 shared publications - Inma Diaz Alvarez
Department of Radiation Oncology, Hospital Universitario de Terrassa (CST), 08221 Terrassa, Spain
2 shared publications - Jesús Muñoz-Rodriguez
Corporació Sanitària Parc Taulí, Spain
2 shared publications Jesús Muñoz-Rodríguez
Department of Urology, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Departament de Cirurgia, Sabadell, Spain
2 shared publications- Josep Maria Sole i Monne
Department of Radiation Oncology, Hospital Universitario de Terrassa (CST), 08221 Terrassa, Spain
2 shared publications
Latest Publications
- Open Access
- 11 March 2026
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 21 (1) , 50
Fracture risk assessment in patients with ileal urinary diversion after radical cystectomy: a comprehensive evaluation integrating bone mineral density, trabecular bone score, and FRAX®
Summary: We conducted a comprehensive fracture risk assessment in 112 men with urinary diversion (UD) after radical cystectomy, integrating bone mineral density (BMD), trabecular bone score (TBS), and FRAX®. A substantial proportion met the diagnostic criteria for osteoporosis or had lower TBS values. These findings support routine skeletal assessment during follow-up. Purpose: Patients undergoing radical cystectomy with UD face an increased risk of fracture; however, this aspect remains poorly investigated. We aimed to provide an integrated evaluation of skeletal health and fracture risk in men with UD. Methods: We conducted a cross-sectional study of 112 men (mean age 70.6 ± 7.98 years; range 50–83) with ileal UD. BMD was measured using DXA, TBS was obtained from lumbar spine DXA images, and 10-year fracture risk was estimated using FRAX®. Logistic regression was used to identify predictors of osteoporosis and lower TBS values. Results: Osteoporosis was identified in 32.1% of patients, and 40.2% were classified in the lowest TBS category (TBS < 1.23). Only 12.5% had normal results for both BMD and TBS. Median FRAX-MOF was 3.9% (IQR 2.7–6.05) without BMD, 5.3% (2.98–7.82) with BMD, and 5.8% (3.4–9.5) when adjusted for TBS. Median FRAX-HIP was 1.35% (0.7–2.78), 1.8% (0.9–4.55) with BMD, and 2% (1–5.2) with TBS adjustment. Age (per year, OR = 1.11, 95% CI 1.02–1.20; p = 0.012) and BMI (per kg/m 2 , OR = 0.73, 95% CI 0.62–0.86; p < 0.001) were independently associated with osteoporosis, while serum creatinine (per mg/dL, OR = 2.11, 95% CI 1.08–4.11; p = 0.028), BMI (per kg/m 2 , OR = 0.91, 95% CI 0.83–0.99; p = 0.041), and prior fracture (OR = 5.23, 95% CI 2.08–13.13; p < 0.001) were associated with TBS < 1.23. Metabolic acidosis was not associated with adverse skeletal outcomes or higher FRAX estimates. Conclusions: Men with ileal UD showed reduced bone mass and a notable proportion of low TBS values, consistent with increased skeletal fragility and fracture risk. Structured bone health assessment should be considered during routine follow-up.
- 11 March 2026
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 21 (1) , 50
Open AccessFracture risk assessment in patients with ileal urinary diversion after radical cystectomy: a comprehensive evaluation integrating bone mineral density, trabecular bone score, and FRAX®
Summary: We conducted a comprehensive fracture risk assessment in 112 men with urinary diversion (UD) after radical cystectomy, integrating bone mineral density (BMD), trabecular bone score (TBS), and FRAX®. A substantial proportion met the diagnostic criteria for osteoporosis or had lower TBS values. These findings support routine skeletal assessment during follow-up. Purpose: Patients undergoing radical cystectomy with UD face an increased risk of fracture; however, this aspect remains poorly investigated. We aimed to provide an integrated evaluation of skeletal health and fracture risk in men with UD. Methods: We conducted a cross-sectional study of 112 men (mean age 70.6 ± 7.98 years; range 50–83) with ileal UD. BMD was measured using DXA, TBS was obtained from lumbar spine DXA images, and 10-year fracture risk was estimated using FRAX®. Logistic regression was used to identify predictors of osteoporosis and lower TBS values. Results: Osteoporosis was identified in 32.1% of patients, and 40.2% were classified in the lowest TBS category (TBS < 1.23). Only 12.5% had normal results for both BMD and TBS. Median FRAX-MOF was 3.9% (IQR 2.7–6.05) without BMD, 5.3% (2.98–7.82) with BMD, and 5.8% (3.4–9.5) when adjusted for TBS. Median FRAX-HIP was 1.35% (0.7–2.78), 1.8% (0.9–4.55) with BMD, and 2% (1–5.2) with TBS adjustment. Age (per year, OR = 1.11, 95% CI 1.02–1.20; p = 0.012) and BMI (per kg/m 2 , OR = 0.73, 95% CI 0.62–0.86; p < 0.001) were independently associated with osteoporosis, while serum creatinine (per mg/dL, OR = 2.11, 95% CI 1.08–4.11; p = 0.028), BMI (per kg/m 2 , OR = 0.91, 95% CI 0.83–0.99; p = 0.041), and prior fracture (OR = 5.23, 95% CI 2.08–13.13; p < 0.001) were associated with TBS < 1.23. Metabolic acidosis was not associated with adverse skeletal outcomes or higher FRAX estimates. Conclusions: Men with ileal UD showed reduced bone mass and a notable proportion of low TBS values, consistent with increased skeletal fragility and fracture risk. Structured bone health assessment should be considered during routine follow-up.
- Open Access
CT-Based Quantification of Prostate Volume Change After LHRH-Agonist Androgen Deprivation: A Prospective, Three-Reader Study for Radiotherapy Planning
Introduction: ADT is routinely combined with radiotherapy (RT) for intermediate- and high-risk prostate cancer. While prostate shrinkage may facilitate planning, prospective CT-based, patient-level estimates over short, workflow-relevant intervals are scarce. Methods: We conducted a prospective study of 47 patients starting luteinizing hormone-releasing hormone agonist (LHRHa) therapy (leuprolide, 6-month depot). Prostate volumes were independently contoured by three blinded radiation oncologists on paired CT scans at baseline and ~8 weeks post-injection. The primary outcomes were the mean relative volume change and the proportion achieving a clinically relevant reduction (≥15%). PSA and testosterone were recorded at both time points; correlations and exploratory univariable logistic regression for ≥15% reduction were performed at the patient level. Results: Mean relative volume reduction ranged from −18.5% to −21.3% across observers; ≥60% of patients met the ≥15% threshold (RT-A 61.7%, RT-B 66.0%, RT-C 74.5%). PSA and testosterone decreased substantially (e.g., median PSA from 9.64 to 1.84 nmol/L) and were moderately correlated (Spearman ρ = 0.43, p = 0.002; Pearson r = 0.51, p < 0.001). No baseline clinical, histologic, or biochemical variables reached statistical significance for predicting ≥15% volume reduction; % PSA change showed a non-significant trend (OR 1.03; 95% CI 1.00–1.07; p = 0.076). Conclusions: Short-course LHRHa induced consistent CT-measured cytoreduction, with more than half of cases achieving ≥15% shrinkage within 8 weeks. Prostate downsizing was reproducible across readers and accompanied by marked PSA and testosterone declines, although biochemical responses did not predict volumetric change. These findings support incorporating a short neoadjuvant “window” before RT simulation and highlight the need for larger studies to refine predictors and compare agonist vs. antagonist trajectories.
Open AccessCT-Based Quantification of Prostate Volume Change After LHRH-Agonist Androgen Deprivation: A Prospective, Three-Reader Study for Radiotherapy Planning
Introduction: ADT is routinely combined with radiotherapy (RT) for intermediate- and high-risk prostate cancer. While prostate shrinkage may facilitate planning, prospective CT-based, patient-level estimates over short, workflow-relevant intervals are scarce. Methods: We conducted a prospective study of 47 patients starting luteinizing hormone-releasing hormone agonist (LHRHa) therapy (leuprolide, 6-month depot). Prostate volumes were independently contoured by three blinded radiation oncologists on paired CT scans at baseline and ~8 weeks post-injection. The primary outcomes were the mean relative volume change and the proportion achieving a clinically relevant reduction (≥15%). PSA and testosterone were recorded at both time points; correlations and exploratory univariable logistic regression for ≥15% reduction were performed at the patient level. Results: Mean relative volume reduction ranged from −18.5% to −21.3% across observers; ≥60% of patients met the ≥15% threshold (RT-A 61.7%, RT-B 66.0%, RT-C 74.5%). PSA and testosterone decreased substantially (e.g., median PSA from 9.64 to 1.84 nmol/L) and were moderately correlated (Spearman ρ = 0.43, p = 0.002; Pearson r = 0.51, p < 0.001). No baseline clinical, histologic, or biochemical variables reached statistical significance for predicting ≥15% volume reduction; % PSA change showed a non-significant trend (OR 1.03; 95% CI 1.00–1.07; p = 0.076). Conclusions: Short-course LHRHa induced consistent CT-measured cytoreduction, with more than half of cases achieving ≥15% shrinkage within 8 weeks. Prostate downsizing was reproducible across readers and accompanied by marked PSA and testosterone declines, although biochemical responses did not predict volumetric change. These findings support incorporating a short neoadjuvant “window” before RT simulation and highlight the need for larger studies to refine predictors and compare agonist vs. antagonist trajectories.
- Open Access
- 3 November 2025
- Published by MDPI AG in Preprints.org
CT-Based Quantification of Prostate Volume Change After LHRH-Agonist Androgen Deprivation: A Prospective, Three-Reader Study for Radiotherapy Planning
Introduction : ADT is routinely combined with radiotherapy (RT) for intermediate- and high-risk prostate cancer. While prostate shrinkage may facilitate planning, prospective CT-based, patient-level estimates over short, workflow-relevant intervals are scarce. Methods: We conducted a prospective study of 47 patients starting luteinizing hormone–releasing hormone agonist (LHRHa) therapy (leuprolide, 6-month depot). Prostate volumes were independently contoured by three blinded radiation oncologists on paired CT scans at baseline and ~8 weeks post-injection. The primary outcomes were the mean relative volume change and the proportion achieving a clinically relevant reduction (≥15%). PSA and testosterone were recorded at both time points; correlations and exploratory univariable logistic regression for ≥15% reduction were performed at the patient level. Results: Mean relative volume reduction ranged from −18.5% to −21.3% across observers; ≥60% of patients met the ≥15% threshold (RT-A 61.7%, RT-B 66.0%, RT-C 74.5%). PSA and testosterone decreased substantially (e.g., median PSA from 9.64 to 1.84 ng/mL) and were moderately correlated (Spearman ρ=0.43, p=0.002; Pearson r=0.51, p< 0.001). No baseline clinical, histologic, or biochemical variable reached statistical significance for predicting ≥15% volume reduction; % PSA change showed a non-significant trend (OR 1.03; 95% CI 1.00–1.07; p=0.076). Conclusions: Short-course LHRHa induced consistent CT-measured cytoreduction, with most patients achieving ≥15% shrinkage within 8 weeks. Prostate downsizing was reproducible across readers and accompanied by marked PSA and testosterone declines, although biochemical responses did not predict volumetric change. These findings support incorporating a short neoadjuvant “window” before RT simulation and highlight the need for larger studies to refine predictors and compare agonist vs antagonist trajectories.
- 3 November 2025
- Published by MDPI AG in Preprints.org
Open AccessCT-Based Quantification of Prostate Volume Change After LHRH-Agonist Androgen Deprivation: A Prospective, Three-Reader Study for Radiotherapy Planning
Introduction : ADT is routinely combined with radiotherapy (RT) for intermediate- and high-risk prostate cancer. While prostate shrinkage may facilitate planning, prospective CT-based, patient-level estimates over short, workflow-relevant intervals are scarce. Methods: We conducted a prospective study of 47 patients starting luteinizing hormone–releasing hormone agonist (LHRHa) therapy (leuprolide, 6-month depot). Prostate volumes were independently contoured by three blinded radiation oncologists on paired CT scans at baseline and ~8 weeks post-injection. The primary outcomes were the mean relative volume change and the proportion achieving a clinically relevant reduction (≥15%). PSA and testosterone were recorded at both time points; correlations and exploratory univariable logistic regression for ≥15% reduction were performed at the patient level. Results: Mean relative volume reduction ranged from −18.5% to −21.3% across observers; ≥60% of patients met the ≥15% threshold (RT-A 61.7%, RT-B 66.0%, RT-C 74.5%). PSA and testosterone decreased substantially (e.g., median PSA from 9.64 to 1.84 ng/mL) and were moderately correlated (Spearman ρ=0.43, p=0.002; Pearson r=0.51, p< 0.001). No baseline clinical, histologic, or biochemical variable reached statistical significance for predicting ≥15% volume reduction; % PSA change showed a non-significant trend (OR 1.03; 95% CI 1.00–1.07; p=0.076). Conclusions: Short-course LHRHa induced consistent CT-measured cytoreduction, with most patients achieving ≥15% shrinkage within 8 weeks. Prostate downsizing was reproducible across readers and accompanied by marked PSA and testosterone declines, although biochemical responses did not predict volumetric change. These findings support incorporating a short neoadjuvant “window” before RT simulation and highlight the need for larger studies to refine predictors and compare agonist vs antagonist trajectories.
- 1 July 2017
- Published by Elsevier in Revista Internacional de Andrología
- Vol. 15 (3) , 123-126
Pancreatitis, una presentación inusual de aumento escrotal
- 1 July 2017
- Published by Elsevier in Revista Internacional de Andrología
- Vol. 15 (3) , 123-126
Pancreatitis, una presentación inusual de aumento escrotal